Progyny's stock surged 22.08% during intraday trading on Friday, marking a significant upward movement for the women's health benefits provider.

The sharp rise follows the company's release of first-quarter 2026 financial results that substantially exceeded analyst expectations. Progyny reported adjusted earnings per share of $0.50, beating consensus estimates of $0.30 by 66.67%, while revenue of $328.5 million also came in above expectations. The company's net income saw a substantial 60.9% year-over-year increase to $24.2 million, with gross margin expanding to 25.3%.

Adding to the positive momentum, Progyny raised its full-year adjusted EPS outlook to a range of $1.98 to $2.09, up from previous guidance. Furthermore, Bofa Global Research raised its price objective on Progyny to $29.00 from $27.00, reflecting increased analyst confidence in the company's growth prospects despite macroeconomic uncertainty.